目的:观察恩度联合含铂方案治疗非小细胞肺癌的疗效及安全性。方法:恩度联合NP和GP方案治疗非小细胞肺癌2～6个周期,治疗前及治疗后对目标病灶进行CT检查及病灶测量,达稳定(SD)以上的患者4周后再次复查评价疗效;化疗期间每周查血常规及心电图1次,化疗后查血常规、肝肾功能、心电图,并观察记录治疗引起的毒副反应。结果:初治有效率为35.7%,复治有效率为20%,总有效率31.6%;初治收益率92.9%,复治收益率60%,总受益率84.2%;化疗周期越长,有效率及受益率越高;毒副反应有白细胞下降、恶心呕吐、贫血、心律失常、便秘、疼痛及转氨酶升高。结论:恩度联合NP和GP方案化疗有效率和临床受益率高,且并增加化疗的不良反应,安全性好。 Objective: To observe the efficacy and safety of Endo combined with platinum-containing regimen in the treatment of non-small cell lung cancer. Methods: Endu combined with NP and GP regimen for 2 ~ 6 cycles of non-small cell lung cancer. Before treatment and after treatment, the CT examination and lesion measurement of the target lesion were performed. Patients over the stable (SD) were reexamined and evaluated after 4 weeks During chemotherapy, routine blood tests and electrocardiogram (ECG) were performed weekly. After chemotherapy, blood routine, liver and kidney function and electrocardiogram were recorded and the side effects caused by treatment were observed. Results: The effective rate of initial treatment was 35.7%, the effective rate of retreatment was 20%, the total effective rate was 31.6%; the rate of initial treatment was 92.9%, the rate of recovery was 60% and the total rate of return was 84.2% The higher the efficiency and benefit rate; toxic side effects of leukopenia, nausea and vomiting, anemia, arrhythmia, constipation, pain and elevated transaminase. Conclusions: Endu combined with NP and GP regimen has high efficiency of chemotherapy and clinical benefit, and it also increases the adverse reactions of chemotherapy and has good safety.